Adhera Therapeutics, Inc.

ATRXOTCHealthcare● Active

$0.00

$-0.00(-0.00%)

Market Cap$722

P/E Ratio—

52W High$0.01

52W Low$0.000099999997

Avg Volume354

Open$0.00

Beta3.73

Free Cash Flow Financials Revenue

Adhera Therapeutics, Inc. (ATRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ATRX · free cash flow · updated Jun 9, 2026

Core FCF metrics

ATRX · FCF · TTM · margin & CAGR

Free cash flow was −$1.4M for FY2022 (fiscal year ending 2022-12-31), down 112.8% year-over-year

FY2022 Free Cash Flow−$1.4M▼ -112.8% YoY

Trailing 12M (TTM)−$808,155trailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ATRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2022Latest−$1.4M(0M)−$1.4M▼ 112.8%—

FY2021−$665,000(0M)−$665,000▼ 13.1%—

FY2020−$588,000(0M)−$588,000▲ +93.3%—

FY2019−$8.7M(0M)−$8.7M▲ +9.8%—

FY2018−$9.6M(0M)−$9.7M▼ 492.2%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ATRX · P/FCF · FCF yield · FCF per share

Adhera Therapeutics, Inc. (ATRX) reported negative free cash flow of −$0.00B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2022 · 2022-12-31

Cash flow statement summary

ATRX · cash flow statement · operating / investing / financing

For FY2022, Adhera Therapeutics, Inc. generated −$1.4M in operating cash flow and spent 0M in capital expenditures, yielding −$1.4M in free cash flow.

Operating Activities

−$1.4M

Cash from core business operations

2022-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2022-12-31

Financing Activities

+$1.4M

Buybacks, dividends & debt

2022-12-31

FCF FormulaOperating CF (−$1.4M) − |CapEx| (0M) = FCF (−$1.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ATRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Adhera Therapeutics, Inc.YOU

ATRX

−$1.4M-112.8%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Adhera Therapeutics, Inc. (ATRX) reported free cash flow of −$1.4M for FY2022 (fiscal year ending 2022-12-31), down 112.8% year-over-year.

Based on available data, Adhera Therapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $285,000 in FY2013.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ATRX free cash flow · 8 questions

Adhera Therapeutics, Inc. free cash flow was −$1.4M for FY2022, down 112.8% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$808,155.

ATRX free cash flowATRX FCFATRX FCF 2022ATRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Adhera Therapeutics, Inc. · Adhera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026